Featured past event: ASTMH Symposium - Severe Malaria: improving the continuum of care
Find out more
The Severe Malaria Observatory: Experience. Evidence. Guidance.
Click here to see what you missed in our last newsletter. To receive upcoming newsletters, please subscribe.
Seasonal malaria chemoprevention (SMC) aims to prevent malaria in children during the high malaria transmission season. The Achieving Catalytic Expansion of SMC in the Sahel (ACCESS-SMC) project sought to remove barriers to the scale-up of SMC in seven countries in 2015 and 2016. We evaluated the project, including coverage, effectiveness of the intervention, safety, feasibility, drug resistance, and cost-effectiveness.
La présente étude a été réalisée pour identifier les obstacles et les opportunités rencontrés dans la prise en charge du paludisme grave afin de réduire la mortalité associée à cette maladie en RDC.
The Severe Malaria Observatory is pleased to announce the launch of its French website. This website will be a welcome addition which will assist the malaria community and communities impacted by malaria in French speaking countries to access information on severe malaria prevention, treatment as well as national and international policies and guidance. The French website can be found at www.severemalaria.org/fr
Her Excellency Rebecca Akuffo Addo, First Lady of the Republic of Ghana entreats all African leaders to fully commit to protecting young girls, so they do not die from malaria.
When severe malaria is suspected in children, WHO recommends pre-treatment with a single rectal dose of artesunate before referral to an appropriate facility. This was an individually randomized, open-label, 2-arm, cross-over clinical trial in 83 Congolese children with severe falciparum malaria, to characterize the pharmacokinetics of rectal artesunate. At admission, children received a single dose of rectal artesunate (10 mg/kg) followed 12 hours later by intravenous artesunate (2.4 mg/kg) or the reverse order. All children also received standard doses of intravenous quinine. Artesunate and dihydroartemisinin were measured at eleven fixed intervals, following 0- and 12-hour drug administrations. Clinical, laboratory and parasitological parameters were measured.
This study intended to inform future programming in relation to the role that Information – Education – Communication (IEC) could play in enhancing this continuum of care. It hypothesized that community exposure to targeted IEC would increase early presentation by the caregiver at the village health clinic (VHC) for Rectal Artesunate (RAS) and the caregiver acceptance of RAS; and that community health worker (CHW/HSA) exposure to a targeted toolkit would increase appropriate assessment, administration of RAS and referral, and in turn enhance prompt compliance with referral instructions among caregivers.